Diabetes Drugs Spark Vision Loss Fears

Glucagon-like peptide (GLP)-1 drugs, commonly prescribed for diabetes management and weight loss, are now under scrutiny for potential adverse effects on vision. These medications mimic natural hormones to regulate blood sugar, slow digestion, and reduce appetite. The impending expiry of the semaglutide patent in India, expected around March 20, 2026, could lead to a surge in generic versions, prompting ophthalmologists to highlight ocular risks.

Ophthalmologists identify two main categories of risks. The first is the progression of diabetic retinopathy, a diabetes-related retinal condition, which can worsen if blood sugar levels are rapidly normalized. The second, rarer but more severe risk, is non-arteritic anterior ischaemic optic neuropathy (NAION), or 'eye stroke', causing sudden, often irreversible vision loss due to optic nerve damage.

Further complications for patients with existing diabetic retinopathy include macular edema (retinal swelling) and vitreous hemorrhage (bleeding within the eye), potentially leading to significant visual decline. While global studies have indicated these risks, Indian medical professionals stress the need for India-specific data. They also note that individual susceptibility plays a role, and the drugs themselves may not be solely to blame.

Experts advocate for a balanced approach, recommending that the use of GLP-1 drugs not be discouraged for medically indicated patients. They propose stratifying patients into risk categories based on their diabetic profile, eye health, and overall condition. Crucially, patients must take these medications only under prescription and follow a treatment plan guided by a diabetologist, coupled with regular ophthalmic evaluations.